Standard BioTools Acquires Sengenics from Summa Equity

10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities

June 10, 2026

Biotechnology

10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.

Illumina Acquires SomaLogic from Standard BioTools

January 30, 2026

Healthcare Services

Illumina, Inc. completed its acquisition of SomaLogic, adding data-driven proteomics technology to expand its multiomics portfolio. The deal was for $350 million in upfront cash at closing, plus up to $75 million in near-term performance-based milestones/royalties, with Illumina expecting to fund the transaction with cash on hand.

Standard BioTools and SomaLogic Planned Merger

December 22, 2023

Healthcare Services

SomaLogic, Inc. announced a proposed merger with Standard BioTools Inc., but several SomaLogic shareholders publicly urged a “no” vote. Tikvah Management and Madryn Asset Management criticized the merger on grounds including alleged undervaluation, process and disclosure concerns, and quality of Standard BioTools’ business and balance sheet.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.

Summa Equity Acquires Majority Stake in Sengenics

October 14, 2020

Biotechnology

Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.

Summa Equity Acquires Olink Proteomics

March 13, 2019

Biotechnology

Summa Equity has acquired a majority stake in Olink Proteomics (Olink AB), a Uppsala-based life science company specializing in proteomics and protein biomarker discovery. The transaction is financed with senior secured/unitranche financing provided by EQT Credit and will support Olink's global scaling and continued product and service development.